U-Ploid, a venture-backed biotechnology company developing next-generation fertility therapeutics, is pleased to announce the appointment of Professor Alison Campbell to its Advisory Board. In this key role, Professor Campbell will provide strategic guidance on company research programmes, working closely with the U-Ploid team to drive innovation in fertility treatments.
The agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.
David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer.
Spin-out company Alethiomics, focused on the development of innovative treatments for blood cancers, is Oxford through-and-through. Founded by Clinician Scientists who run neighbouring laboratories at the University\u2019s MRC Weatherall Institute of Molecular Medicine, seed financed by Oxford Science Enterprises and located at the BioEscalator, the company\u2019s early years have been immersed in the Oxford innovation ecosystem.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that the Company has promoted Dr Hsin Loke to Chief Operating Officer (COO) and Jon Roffey Ph.D. to Senior Vice President, Discovery and Non-Clinical, effective immediately.
TechBio startup, Exogene, is leveraging artificial intelligence (AI) to develop innovative immunotherapies with the potential to eliminate untreatable solid tumours in cancer patients. Through a collaboration with German company Alithea Bio, Exogene hopes to speed up cancer immunotherapy discovery and make it more cost-effective.
Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO), effective 1 December 2024. He will take on the role from Dr Ali Jazayeri, who is leaving OMass to pursue other opportunities.
Through UK-Germany Collaborative R&D funding, Exogene is collaborating with the German company Alithea Bio, aiming to accelerate cancer immunotherapy discovery and make it more cost-effective.
CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.
Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announces that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a \u2018top 100\u2019 poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.
In its first major refresh since its establishment in 2018, the BioEscalator is delighted to welcome five leading University of Oxford academics and innovators to its Management Board. Professors Catherine Green OBE, Beth Psaila, Molly Stevens DBE, Krina Zondervan and Peter Callow, Financial Controller of the Medical Sciences Division at the University of Oxford. The Management Board provides a source of expertise for BioEscalator tenants and works to enhance research at the University by building strong links with small life sciences companies.
Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson & Johnson*.
Moa Technology is pleased to announce that Lee Sweetlove, Professor of Plant Sciences at the University of Oxford, has joined our team. Professor Sweetlove will be working to further understanding of the novel herbicidal modes of action discovered by Moa, which we are currently developing into safe, effective and affordable solutions to protect harvests from crop-killing weeds.
\u2018Mighty oaks from little acorns grow.\u2019 And so it is with novel herbicide developer Moa Technology, which has grown from four people when it first became a BioEscalator tenant to a company of 85 with research facilities in Oxford and Yorkshire.
Enara Bio today announces the closing of a $32.5M Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, including RA Capital, Samsara BioCapital and SV Health Investors.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the candidate nomination of its lead program targeting the melanocortin-2 (MC2) receptor and key appointments to support its progress towards becoming a clinical-stage company.
![\"Professor](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/u-ploid-biotechnologies-announces-the-appointment-of-professor-alison-campbell-to-its-advisory-board/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n